ArticleClinical pharmacology and therapeutics2026
Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
External control (EC) arms using routine data can be used as comparators in clinical trials under certain conditions. The objective of this study was to assess the ability of an EC arm to replicate outcomes of a randomized controlled trial (RCT) arm receiving the same treatment strategy in advanced stage classical Hodgkin lymphoma and serve as comparator in future trials. Using the prospective real-world data in lymphoma and survival in adults (REALYSA) cohort, we constructed an EC arm by applying eligibility criteria of the AHL2011 phase III RCT. Propensity score (PS) weighting was used to balance baseline characteristics between the EC arm and the RCT arm that received the same treatment. Progression-free survival (PFS) and overall response rate (ORR) at the end of first-line treatment were estimated in both arms. Hazard ratio (HR) for PFS and odds ratio (OR) for ORR were estimated using the EC arm as reference. A sensitivity analysis evaluated PS matching. Four hundred and ten RCT patients and 191 EC patients were analyzed. After PS weighting, patients' characteristics were well-balanced between arms. PFS estimates were similar in RCT and EC arms with an HR close to 1 (HR, 0.98; 95% CI, 0.59-1.62). ORR estimates were comparable in both arms. Weighting performed better than matching. Using PS weighting gave similar outcomes in the EC arm compared with the RCT arm. Our results suggest that EC studies using routine care data could be considered in the development of strategies for advanced Hodgkin lymphoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.